search

4D Molecular Therapeutics Inc (FDMT)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing
Sep 20, 2026

4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing

David Kirn, Director, President, and Chief Executive Officer of 4D Molecular Therapeutics, sold 58,333 shares of the company's stock on September 14, 2026. This transaction amounted to $811,004. The full details of this insider sale are available through a premium subscription to MT Newswires.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Somewhat-Bearish
Kirn David Executes Open-Market Sale of 58,333 Shares in 4D Molecular Therapeutics
Sep 17, 2026

Kirn David Executes Open-Market Sale of 58,333 Shares in 4D Molecular Therapeutics

Kirn David sold 58,333 shares of 4D Molecular Therapeutics (FDM) on September 14, 2026, at a price of $13.90 per share. This open-market sale represented approximately 7.1% of his previous holdings in the company. Following the transaction, Kirn David retained 767,486 shares of 4D Molecular Therapeutics.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish